BerGenBio

Legal Proceedings Report • Oct 31, 2023

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

BERGEN, Norway, October 31, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, today announced that a poster highlighting data from

pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC)

patients treated with bemcentinib, a highly selective AXL inhibitor in

combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) will be

presented at the Society for Immunotherapy for Cancer (SITC) meeting being held

on November 1-5, 2023 in San Diego, California.

The poster abstract was published today in the Journal for Immunotherapy of

Cancer (JITC), an open-access journal. The full poster will be available on

BerGenBio's website shortly following presentation on November 4th.

Poster Details

Title: Bemcentinib + Pembrolizumab show promising efficacy in metastatic NSCLC

patients harboring mutations associated with poor prognosis: exploratory sub

-analysis from the BGBC008 trial

Poster Board Number: 598

Presentation Time: Saturday, Nov. 4, 2023 beginning at 0900 Pacific Time

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of

Merck & Co., Inc., Rahway, NJ, USA

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About Bemcentinib

Bemcentinib is a potentially first-in-class, potent and highly selective

inhibitor of the tyrosine kinase AXL.  Extensive studies confirm the ability to

combine bemcentinib with immune checkpoint inhibitors, chemotherapies and

targeted therapies with the goal of improving a patient's immune response and

delaying the development of chemoresistance.  Bemcentinib is currently being

investigated in combination with immune checkpoint inhibition and chemotherapy

in first line NSCLC patients harboring mutations in the STK11 gene, a known

prognostic factor of poor response to existing therapies.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visitwww.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.